Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

The most common cause of adult GHD in previous studies was due to pituitary tumors or their treatment.

Sheehan's syndrome classically refers to postpartum hypopituitarism due to pituitary necrosis occurring secondary to massive bleeding at or just after delivery.

While severe GHD is a well-established feature of Sheehan's syndrome, the effects of Growth hormone replacement therapy (GHRT) in these patients has not been extensively investigated.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, women only.

The study comprised 14 severely GH-deficient patients with Sheehan's syndrome with a mean age of 49.4+/-7.9 yr.

Blood pressure, lipid profile, biochemical parameters, anthropometric measurements including body mass index (BMI), waist and waist to hip ratio (W/H), and bone mineral density (BMD) were investigated before and at 3, 6, 12 and 18 months of the GHRT.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Pressure, Bone Density, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.